Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

doi:10.1200/JCO.2015.65.4889

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2016

DuBois Steven G, Marachelian Araz, Fox Elizabeth, Kudgus Rachel A, Reid Joel M, Groshen Susan, Malvar Jemily, Bagatell Rochelle, Wagner Lars, Maris John M, Hawkins Randall, Courtier Jesse, Lai Hollie, Goodarzian Fariba, Shimada Hiroyuki, Czarnecki Scarlett, Tsao-Wei Denice, Matthay Katherine K, Mosse Yael P

Abstract excerpt

PURPOSE: Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in neuroblastoma. Irinotecan and temozolomide have activity in patients with advanced neuroblastoma. The goal of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinotecan and temozolomide in this population. PATIENTS AND METHODS: Patients age 1 to 30 years with relapsed or refractory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinase A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azepines

Share to Camptothecin

Share to Dacarbazine

Share to Drug Administration Schedule

Share to Irinotecan

Share to Maximum Tolerated Dose

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 26884555
DOI: 10.1200/JCO.2015.65.4889
PMCID: PMC4872349

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.PMID 26884555Read ↗

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A InhibitorsSemantic proximity Read ↗

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.Semantic proximity Read ↗

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma CellsSemantic proximity Read ↗

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.Semantic proximity Read ↗

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitorSemantic proximity Read ↗

Aurora Kinases as Anticancer Drug TargetsSemantic proximity Read ↗

Aurora kinase inhibitors as anti-cancer therapySemantic proximity Read ↗

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.Semantic proximity Read ↗

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)Semantic proximity Read ↗

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialSemantic proximity Read ↗

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin (IREC) for refractory or relapsed neuroblastomaSemantic proximity Read ↗

Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.